AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Rab5 GDP/GTP exchange factor

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries.

 Fig. 1. The sreening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q9UJ41

UPID:

RABX5_HUMAN

Alternative names:

RAP1; Rabaptin-5-associated exchange factor for Rab5; Rabex-5

Alternative UPACC:

Q9UJ41; B4DZM7; Q3HKR2; Q3HKR3; Q53FG0

Background:

The Rab5 GDP/GTP exchange factor, also known as RAP1, Rabaptin-5-associated exchange factor for Rab5, and Rabex-5, plays a pivotal role in cellular processes. It functions as a Rab effector protein, facilitating the linkage between gamma-adaptin, RAB4A, or RAB5A. This protein is crucial in endocytic membrane fusion and the membrane trafficking of recycling endosomes, enhancing nucleotide exchange on RAB5A. Additionally, it possesses the capability to act as a ubiquitin ligase, further underscoring its versatility in cellular functions.

Therapeutic significance:

Understanding the role of Rab5 GDP/GTP exchange factor could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.